Latest Us Market News

HydraLyte USA has completed the divestiture of its non-US assets, wiping out debt and boosting cash reserves to US$3.2 million, while focusing its growth strategy on the US ecommerce market with a 28% quarterly revenue increase.

Ovanti Limited has made significant strides in its plan to enter the US Buy Now Pay Later market, delivering a comprehensive strategic report and strengthening its executive team to support expansion.

Echo IQ confirms the material significance of its pre-submission FDA meeting for EchoSolv HF, marking a pivotal step toward US market entry and commercialisation.

Inventis Limited reported robust Q2 progress with over $5.7 million in confirmed orders and a $2.5 million capital raise underway in the US, signaling strong momentum in its technology-driven growth strategy.

HITIQ Limited’s largest shareholder, Harmil Angel Investments, is converting $1.6 million in convertible notes into shares, while the company revamps its advisory mandate to attract US investors.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

Nova Eye Medical Limited is raising A$6.6 million to strengthen its financial position following resolved supply chain disruptions, while reporting strong sales growth and nearing profitability in its glaucoma division.

Nova Eye Medical has completed a $6.6 million placement to fund growth initiatives, supported by strong global sales growth and a major shareholder commitment. The capital raise aims to bolster sales teams and product development as the company targets profitability in its glaucoma division.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

Tasman Resources has identified six promising drill targets at its Parkinson Dam gold project in South Australia, supported by advanced geophysical analysis and a new high-resolution gravity survey. The company also highlights ongoing investment in Eden Innovations and strategic funding moves.

HeraMED reports a surge in its HeraCARE platform users and secures $4.1 million in new funding, underpinning its expansion in the US maternity care market and integration with major health systems.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.